TEVA fell nearly 5% after missing on revenue expectations. Its 18% decline in revenues was nothing to write home about either. Since Teva and Endo both compete in the generic drug space, any disappointment from Teva often hurts Endo as well. Endo reports Q2 earnings Wednesday August 8th and its results could be a completely different story vis-a-vis Teva.
ENDP has risen by over 90% over the past two months. Short sellers have been hemorrhaging ever since, and could be trapped. Read more:
